CN104689330A - Antitumor drug PEGylation and applications of antitumor drug PEGylation in reversal of tumor multidrug resistance - Google Patents
Antitumor drug PEGylation and applications of antitumor drug PEGylation in reversal of tumor multidrug resistance Download PDFInfo
- Publication number
- CN104689330A CN104689330A CN201310659170.6A CN201310659170A CN104689330A CN 104689330 A CN104689330 A CN 104689330A CN 201310659170 A CN201310659170 A CN 201310659170A CN 104689330 A CN104689330 A CN 104689330A
- Authority
- CN
- China
- Prior art keywords
- antitumor drug
- tumor
- pegization
- drug
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses antitumor drug PEGylation and applications of the antitumor drug PEGylation in reversal of tumor multidrug resistance. The PEGylated antitumor drug is prepared by conjugating activated PEG onto an antitumor drug, and can be used for preparing the drug for reversal of tumor multidrug resistance. According to the present invention, the antitumor drugs (particularly water insoluble drugs) containing amino, carboxyl, hydroxyl and other modifiable groups are PEGylated so as to increase the water solubility, such that excellent characteristics of micelle self-assembly forming, production of invisible nanoparticles or active targeting tumor nanoparticles, drug release behavior regulation, system toxicity reducing, biological half-life improving, EPR effect production, tumor passive/active targeting production, tumor multidrug resistance reversal and the like are provided, and good clinical application prospects are provided.
Description
Technical field
The invention belongs to anti-tumor medicine technical field, be specifically related to a kind of antitumor drug PEGization and the application on reverse multiple drug resistance of tumor thereof.
Background technology
Malignant tumor is one of disease of serious harm human health.International anti-cancer alliance declares, the summation of the death toll that the number of the death because of cancer every year causes considerably beyond these three kinds of diseases of malaria, acquired immune deficiency syndrome (AIDS) and tuberculosis.To the year two thousand twenty, the whole world may increase cancer patient 1,500 ten thousand people every year newly.Current China tumor incidence is about 2,00/,100,000, the annual new cancer cases of China about more than 2,200,000, and reach more than 6,000,000 controlling patient every year, medical expense, more than 1,500 hundred million, dies from cancer occurrence numbers every year more than 1,600,000.Oneself becomes one of global health strategy emphasis to control cancer.
At present, anti-cancer therapies mainly comprises surgical operation therapy, radiation and chemotherapy clinically, and wherein chemotherapy is the main means for the treatment of of cancer.But the generation of tumor cell multidrug resistance (multidrug resistance, MDR) is the main cause of current cancer chemotherapy failure.Therefore, focus and difficult point that tumor multi-medicine drug-resistant has become field of cancer is overcome.
The generation of tumor multidrug-resistance has number of mechanisms, mainly comprises: the overexpression of the P-glycoprotein of multidrug resistance gene (MDR1 gene) and coding thereof; The activity of glutathion and relevant enzyme increases; Expression of MRP increase etc.Medicine for the reverse multiple drug resistance of tumor of above mechanism has a lot, mainly comprises: cyclosporin A and derivant thereof, Progesterone, quinine etc.But it is unstable in vivo, tumor-targeting is poor and toxic and side effects is excessive.Therefore, the medicament research and development of the efficient reverse multiple drug resistance of tumor of low toxicity remains the focus that people pay close attention to.
Rapamycin (RAPA) is white crystalline solid, atomic water-soluble, is soluble in the organic solvents such as methanol, ethanol, chloroform.Rapamycin has the effects such as antitumor, antifungal and immunosuppressant.
Paclitaxel (PTX) all has good effect to kinds of tumors, but its water solublity is low, toxic and side effects is strong, and these all strongly limit its application clinically, and long-time use easily produces drug resistance phenomenon.
Amycin (DOX) is the antitumor drug that Clinical practice is maximum so far, but it has obvious accumulative cardiac toxicity, stopped treatment of sometimes having to, and is also easy to produce drug resistance simultaneously, causes chemotherapy failure.
Polyethylene Glycol (PEG) is the polymer substance that pH is neutral, nontoxic, have excellent hydrophilic and biocompatibility, and the only a few ratified by FDA can as one of polymer of injection drug in body.
Summary of the invention
The object of the present invention is to provide a kind of antitumor drug PEGization and the application on reverse multiple drug resistance of tumor thereof; The present invention by containing amino, carboxyl and hydroxyl etc. can the antitumor drug (particularly poorly water soluble drugs) of modification group after PEGization; water solublity can be improved; have and self assembly can form micelle, make invisible nano particle or active targeting tumor nanoparticle; the release behavior of regulating medicine; mitigation system toxicity, raising biological half-life, produces EPR effect and tumor is passive, active targeting; and the good characteristic such as reverse multiple drug resistance of tumor, there is good potential applicability in clinical practice.
The object of the invention is to be achieved through the following technical solutions:
First aspect, the present invention relates to a kind of PEGization antitumor drug, and described PEGization antitumor drug obtains by the PEG of activation being coupled to preparation on antitumor drug.
Preferably, the number-average molecular weight of described PEG is 0.1K ~ 1000K.
Preferably, described PEGization antitumor drug can connect target head.
Preferred, described target head comprises folic acid, biotin, RGD, antibody or aptamer.
Second aspect, the present invention relates to the purposes of a kind of above-mentioned PEGization antitumor drug in the medicine preparing reverse multiple drug resistance of tumor.
Preferably, the antitumor drug in described PEGization antitumor drug comprises the antitumor drug of cell toxicant class.
Preferred, the antitumor drug of described cell toxicant class is the medicine acting on the medicine of DNA chemical constitution, the medicine affecting Nucleic acid, the medicine acting on transcribed nucleic acid, topoisomerase enzyme inhibitor or disturb tubulin synthesis.
Preferably, described tumor is have one or more in the inherent multidrug-resistant carcinoma of P-glycoprotein overexpression, acquisition multidrug resistance entity tumor, hematological system tumor.
Preferably, described PEGization antitumor drug self assembly can be formed micelle, makes invisible nano particle or make active targeting tumor nanoparticle.Prepared micelle, invisible nano particle or active targeting tumor nanoparticle can produce EPR effect.Prepared micelle and invisible nano particle have tumor passive target and long blood circulation effect in vivo.
Preferably, the particle size range of described micelle, invisible nano particle or active targeting tumor nanoparticle is 1 ~ 200nm.
Compared with prior art, the present invention has following beneficial effect:
1, the PEG of medicine modifies is the process be coupled to by chemical method by the PEG of activation on medicine, i.e. PEGization; Compared with before modification, there is outstanding advantage after medicine PEGization: 1) dissolubility of medicine improves, 2) Increased Plasma Half-life, 3) pharmacokinetics improves, and 4) immunogenicity of protein drug and antigenicity decline.
2, antitumor drug (as rapamycin, paclitaxel and amycin etc.) self assembly can form invisible nano particle after PEGization, produces EPR effect, has tumor passive target and long blood circulation effect.Experiment in vitro shows, it has obvious reverse effect to MCF-7/ADR cell, and reversal index is respectively 3.02,3.33 and 2.05, and system toxicity declines to some extent, compares proto-drug, and PEG chemical medicine thing is to the IC of MCF-7 cell
50value rises 5.1,13.0 and 6.4 times respectively.This good characteristic can be used for the treatment of tumor multi-medicine drug-resistant.
Accompanying drawing explanation
By reading the detailed description done non-limiting example with reference to the following drawings, other features, objects and advantages of the present invention will become more obvious:
Fig. 1 is PEG-RAPA
1h NMR spectrogram;
Fig. 2 is after the rapamycin treatment MCF-7 cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Fig. 3 is after the rapamycin treatment MCF-7/ADR cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Fig. 4 is after the PEG-RAPA process MCF-7 cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Fig. 5 is after the PEG-RAPA process MCF-7/ADR cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Fig. 6 is PEG-PTX
1h NMR spectrogram;
Fig. 7 is after the taxol treatment MCF-7 cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Fig. 8 is after the taxol treatment MCF-7/ADR cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Fig. 9 is after the PEG-PTX process MCF-7 cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Figure 10 is after the PEG-PTX process MCF-7/ADR cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Figure 11 is PEG-DOX
1h NMR spectrogram;
Figure 12 is after the amycin process MCF-7 cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Figure 13 is after the amycin process MCF-7/ADR cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Figure 14 is after the PEG-DOX process MCF-7 cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell;
Figure 15 is after the PEG-DOX process MCF-7/ADR cell with variable concentrations, by the survival rate of MTT colorimetric determination tumor cell.
Detailed description of the invention
Below in conjunction with the drawings and specific embodiments, the present invention is described in detail.Following examples will contribute to those skilled in the art and understand the present invention further, but not limit the present invention in any form.It should be pointed out that to those skilled in the art, without departing from the inventive concept of the premise, can also make certain adjustments and improvements.These all belong to protection scope of the present invention.
embodiment 1
For PEG-RAPA, the mensuration of its building-up process, physicochemical property and the reverse effect to MCF-7/ADR cell thereof are described:
The synthesis of PEG-RAPA: get mPEG-COOH88mg and be dissolved in the anhydrous methylene chloride of 10mL ice, then add the rapamycin of 107mg, the DMAP of DCC and 15mg of 30mg.Naturally room temperature is warming up to, stirring reaction 3d.Filter after completion of the reaction, absolute ether precipitates 2 times, then by precipitate vacuum drying and get final product.PEG-RAPA's (PEGization rapamycin)
1h NMR spectrogram as shown in Figure 1.
The preparation of PEG-RAPA micelle and particle size determination thereof: PEG-RAPA micelle adopts solid dispersion method preparation.Get the acetonitrile that 1mg PEG-RAPA is dissolved in 100 μ L, after naturally volatilizing, be dissolved in 2ml ultra-pure water, vortex 3min, the centrifugal 10min of ultrasonic 5min, 12000r/min, get supernatant with 0.45 μm of filtering with microporous membrane and get final product.
The particle diameter dynamic light scattering method (DLS) of PEG-RAPA micelle measures: experimental light sources is 4.0mWHe-Ne laser, optical maser wavelength 633nm, measures angle 173 °.All measuring tempeature are all 25 DEG C, and retest three times, averages.Experimental result is in table 1.
The mensuration of PEG-RAPA dissolubility: adopt weight reduction to measure.Getting a certain amount of PEG-RAPA is dissolved in the ultra-pure water of 2mL, is stirred well to and reaches dissolution equilibrium, filters, the PEG-RAPA of the undissolved drying of accurate weighing.The solvent volume of the dissolubility=total amount-undissolved amount of thing of getting it filled ()/add.More than experiment measures at 25 DEG C.Experimental result is in table 1.
The table dissolubility of 1PEG-RAPA and the particle diameter of PEG-RAPA micelle
| PEG chemical medicine thing | Dissolubility (mg/ml) | Particle diameter (nm) | PDI |
| PEG-RAPA | 16.7 | 55.7±2.2 | 0.132±0.007 |
The mould rope of thunder handkerchief its water solublity after PEGization increases greatly as shown in Table 1, and dissolubility becomes 16.7mg/mL (dissolubility amounting to into rapamycin is 5.01mg/mL).It self assembly can form micelle in water simultaneously, and particle diameter is 55.7nm, and uniform particle diameter, PDI is 0.132.
MCF-7/ADR cell measures the drug resistance multiple of rapamycin: MCF-7 and MCF-7/ADR cell is inoculated in 96 orifice plates with 4000, every hole respectively, every pore volume 200 μ L.After cell attachment, culture medium replaces with the culture medium containing free drug, continues to cultivate 48h.Then sucking-off culture medium solution, adds 1640 culture medium (not containing serum) of the 200 μ L containing 0.5mg/mL MTT.After 4h, MTT solution is sucked, and the DMSO solution adding 200 μ L dissolves.Then their light absorption values at 490nm place are measured by microplate reader.Each concentration do 5 parallel.Calculate cell proliferation suppression ratio by formula (1), and calculate the drug resistance multiple of medicine by following formula (2):
Cell proliferation suppression ratio=(control group A value-drug treating group A value)/control group A value × 100% (1)
Drug resistance multiple=IC
50(MCF-7/ADR cell)/IC
50(MCF-7 cell) (2)
Result is as shown in Fig. 2, Fig. 3 and table 2:
Table 2 rapamycin is to the IC of MCF-7 and MCF-7/ADR cell
50value and drug resistance multiple
MCF-7/ADR cell has very strong drug-resistant effect to rapamycin as shown in Table 2, can be used for the correlational study of multidrug resistance.
PEG-RAPA measures the cytotoxic effect of MCF-7 cell the reverse exponential sum of MCF-7/ADR cell: be inoculated in 96 orifice plates by MCF-7/ADR, MCF-7 cell being in exponential phase with the density in 4000/hole, every pore volume 200 μ L, is placed in incubator and cultivates.After cell attachment, culture medium replaces with the culture medium containing PEG-RAPA, continues to cultivate 48h.Then sucking-off culture medium solution, adds 1640 culture medium (not containing serum) of the 200 μ L containing 0.5mg/mLMTT.After 4h, MTT solution is sucked, and the DMSO solution adding 200 μ L dissolves.Then their light absorption values at 490nm place are measured by microplate reader.Each concentration do 5 parallel.Calculate cell proliferation suppression ratio by formula (1), and calculate reverse index by following formula (3).
Reverse index=IC
50(chemotherapeutics)/IC
50(PEG chemical medicine thing) (3)
Experimental result is as shown in Fig. 4, Fig. 5 and table 3:
Table 3PEG-RAPA is to the IC of MCF-7/ADR, MCF-7 cell
50value and reverse index
Table 3 result shows that rapamycin strengthens to some extent the toxicity of MCF-7/ADR cell after PEGization, and reversing index is 3.02, and have stronger reversing effect, decline to some extent simultaneously to the toxicity of MCF-7 cell, decline multiple is 5.1.
embodiment 2
For PEG-PTX, the mensuration of its building-up process, physicochemical property and the reverse effect to MCF-7/ADR cell thereof are described:
The synthesis of PEG-PTX: get mPEG-COOH88mg, is dissolved in 10mL anhydrous methylene chloride, ice bath to 0 DEG C, then adds the paclitaxel of 100mg, the DMAP of the DCC of 30mg, 15mg, and stirring reaction, is warming up to room temperature naturally, reaction 3d.Filter after completion of the reaction, and use ice ether sedimentation, then by precipitate vacuum drying and get final product.PEG-PTX's (PEG-Toxol)
1h NMR spectrogram as shown in Figure 6.
The preparation of PEG-PTX micelle and particle size determination thereof: PEG-PTX micelle adopts solid dispersion method preparation.Get the acetonitrile that 1mg PEG-PTX is dissolved in 100 μ L, after naturally volatilizing, be dissolved in 2ml ultra-pure water, vortex 3min, the centrifugal 10min of ultrasonic 5min, 12000r/min, get supernatant with 0.45 μm of filtering with microporous membrane and get final product.
The particle diameter dynamic light scattering method (DLS) of PEG-PTX micelle measures: experimental light sources is 4.0mWHe-Ne laser, optical maser wavelength 633nm, measures angle 173 °.All measuring tempeature are all 25 DEG C, and retest three times, averages.Experimental result is in table 4.
The particle diameter of table 4PEG-PTX micelle and PDI
| PEG chemical medicine thing | Particle diameter (nm) | PDI |
| PEG-PTX | 53.4±3.4 | 0.170±0.010 |
PEG-PTX self assembly can form micelle in water as shown in Table 4, and its size is 53.4nm, PDI is 0.170.
MCF-7/ADR cell measures the drug resistance multiple of paclitaxel: MCF-7 and MCF-7/ADR cell is inoculated in 96 orifice plates with 4000, every hole respectively, every pore volume 200 μ L.After cell attachment, culture medium replaces with the culture medium containing free drug, continues to cultivate 48h.Then sucking-off culture medium solution, adds 1640 culture medium (not containing serum) of the 200 μ L containing 0.5mg/mL MTT.After 4h, MTT solution is sucked, and the DMSO solution adding 200 μ L dissolves.Then their light absorption values at 490nm place are measured by microplate reader.Each concentration do 5 parallel.Calculate cell proliferation suppression ratio by formula (1), and press the drug resistance multiple that formula (2) calculates medicine.
Experimental result is as shown in Fig. 7, Fig. 8 and table 5:
Table 5 paclitaxel is to the IC of MCF-7 and MCF-7/ADR cell
50value and drug resistance multiple
MCF-7/ADR cell has very strong drug-resistant effect to paclitaxel as shown in Table 5, can be used for the correlational study of multidrug resistance.
PEG-PTX measures the cytotoxic effect of MCF-7 cell the reverse exponential sum of MCF-7/ADR cell: be inoculated in 96 orifice plates by MCF-7/ADR, MCF-7 cell being in exponential phase with the density in 4000/hole, every pore volume 200 μ L, is placed in incubator and cultivates.After cell attachment, culture medium replaces with the culture medium containing PEG-PTX, continues to cultivate 48h.Then sucking-off culture medium solution, adds 1640 culture medium (not containing serum) of the 200 μ L containing 0.5mg/mLMTT.After 4h, MTT solution is sucked, and the DMSO solution adding 200 μ L dissolves.Then their light absorption values at 490nm place are measured by microplate reader.Each concentration do 5 parallel.Calculate cell proliferation suppression ratio by formula (1), and press formula (3) calculating reverse index.
Experimental result is as shown in Fig. 9, Figure 10 and table 6:
Table 6PEG-PTX is to the IC of MCF-7/ADR, MCF-7 cell
50value and reverse index
Table 6 result shows that paclitaxel strengthens to some extent the toxicity of MCF-7/ADR cell after PEGization, and reversing index is 3.33, and have stronger reversing effect, decline to some extent simultaneously to the toxicity of MCF-7 cell, decline multiple is 13.0.
embodiment 3
For PEG-DOX, the mensuration of its building-up process, physicochemical property and the reverse effect to MCF-7/ADR cell thereof are described:
The synthesis of PEG-DOX: get 210mg mPEG-COOH, 58mg doxorubicin hydrochloride, 23mgNHS, 20mgDCC, 12mgTEA, in 10ml anhydrous methylene chloride, react 3d under room temperature lucifuge nitrogen, filter, dialysis, lyophilization and get final product.PEG-DOX's (PEG amycin)
1h NMR spectrogram as shown in figure 11.
The preparation of PEG-DOX micelle and particle size determination thereof: PEG-DOX micelle adopts solid dispersion method preparation.Get the acetonitrile that 1mg PEG-DOX is dissolved in 100 μ L, after naturally volatilizing, be dissolved in 2ml ultra-pure water, vortex 3min, the centrifugal 10min of ultrasonic 5min, 12000r/min, get supernatant with 0.45 μm of filtering with microporous membrane and get final product.
The particle diameter dynamic light scattering method (DLS) of PEG-DOX micelle measures: experimental light sources is 4.0mWHe-Ne laser, optical maser wavelength 633nm, measures angle 173 °.All measuring tempeature are all 25 DEG C, and retest three times, averages.Experimental result is in table 7.
The particle diameter of table 7PEG-DOX micelle and PDI
| PEG chemical medicine thing | Particle diameter (nm) | PDI |
| PEG-DOX | 51.7±2.1 | 0.161±0.006 |
PEG-DOX self assembly can form micelle in water as shown in Table 7, and its size is 51.7, PDI is 0.161.
MCF-7/ADR cell measures the drug resistance multiple of amycin: MCF-7 and MCF-7/ADR cell is inoculated in 96 orifice plates with 4000, every hole respectively, every pore volume 200 μ L.After cell attachment, culture medium replaces with the culture medium containing free drug, continues to cultivate 48h.Then sucking-off culture medium solution, adds 1640 culture medium (not containing serum) of the 200 μ L containing 0.5mg/mL MTT.After 4h, MTT solution is sucked, and the DMSO solution adding 200 μ L dissolves.Then their light absorption values at 490nm place are measured by microplate reader.Each concentration do 5 parallel.Calculate cell proliferation suppression ratio by formula (1), and press the drug resistance multiple that formula (2) calculates medicine.
Experimental result is as shown in Figure 12, Figure 13 and table 8:
Table 8 amycin is to the IC of MCF-7 and MCF-7/ADR cell
50value and drug resistance multiple
MCF-7/ADR cell has very strong drug-resistant effect to Ah mould's rope as shown in Table 8, can be used for the correlational study of multidrug resistance.
PEG-DOX measures the cytotoxic effect of MCF-7 cell the reverse exponential sum of MCF-7/ADR cell: be inoculated in 96 orifice plates by MCF-7/ADR, MCF-7 cell being in exponential phase with the density in 4000/hole, every pore volume 200 μ L, is placed in incubator and cultivates.After cell attachment, culture medium replaces with the culture medium containing PEG-DOX, continues to cultivate 48h.Then sucking-off culture medium solution, adds 1640 culture medium (not containing serum) of the 200 μ L containing 0.5mg/mLMTT.After 4h, MTT solution is sucked, and the DMSO solution adding 200 μ L dissolves.Then their light absorption values at 490nm place are measured by microplate reader.Each concentration do 5 parallel.Calculate cell proliferation suppression ratio by formula (1), and press formula (3) calculating reverse index.
Experimental result is as shown in Figure 14, Figure 15 and table 9:
Table 9PEG-DOX is to the IC of MCF-7/ADR, MCF-7 cell
50value and reverse index
Table 9 result shows that amycin strengthens to some extent the toxicity of MCF-7/ADR cell after PEGization, and reversing index is 2.05, and have stronger reversing effect, decline to some extent simultaneously to the toxicity of MCF-7 cell, decline multiple is 6.4.
In sum, PEGization antitumor drug of the present invention has the effect of obvious reverse multiple drug resistance of tumor.Further its principle is described below: multidrug resistance produces primarily of the mediation of P-gp glycoprotein, and rapamycin, paclitaxel and amycin are all the substrates of P-gp, above-mentioned antitumor drug changes its chemical constitution (becoming prodrug) after PEGization, from instead of the substrate of P-gp, so can reverse multidrug drug resistance.In the same way, those medicines that can produce drug resistance also can reverse multidrug drug resistance after PEGization.
Above specific embodiments of the invention are described.It is to be appreciated that the present invention is not limited to above-mentioned particular implementation, those skilled in the art can make various distortion or amendment within the scope of the claims, and this does not affect flesh and blood of the present invention.
Claims (10)
1. a PEGization antitumor drug, is characterized in that, described PEGization antitumor drug obtains by the PEG of activation being coupled to preparation on antitumor drug.
2. PEGization antitumor drug as claimed in claim 1, it is characterized in that, the number-average molecular weight of described PEG is 0.1K ~ 1000K.
3. PEGization antitumor drug as claimed in claim 1, it is characterized in that, described PEGization antitumor drug can connect target head.
4. PEGization antitumor drug as claimed in claim 3, it is characterized in that, described target head comprises folic acid, biotin, RGD, antibody or aptamer.
5. the purposes of PEGization antitumor drug in the medicine preparing reverse multiple drug resistance of tumor according to any one of Claims 1 to 4.
6. purposes as claimed in claim 5, it is characterized in that, the antitumor drug in described PEGization antitumor drug comprises the antitumor drug of cell toxicant class.
7. purposes as claimed in claim 6, it is characterized in that, the antitumor drug of described cell toxicant class is the medicine acting on the medicine of DNA chemical constitution, the medicine affecting Nucleic acid, the medicine acting on transcribed nucleic acid, topoisomerase enzyme inhibitor or disturb tubulin synthesis.
8. purposes as claimed in claim 5, is characterized in that, described tumor is have one or more in the inherent multidrug-resistant carcinoma of P-glycoprotein overexpression, acquisition multidrug resistance entity tumor, hematological system tumor.
9. purposes as claimed in claim 5, is characterized in that, described PEGization antitumor drug self assembly can be formed micelle, makes invisible nano particle or make active targeting tumor nanoparticle.
10. purposes as claimed in claim 9, it is characterized in that, the particle size range of described micelle, invisible nano particle or active targeting tumor nanoparticle is 1 ~ 200nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310659170.6A CN104689330A (en) | 2013-12-06 | 2013-12-06 | Antitumor drug PEGylation and applications of antitumor drug PEGylation in reversal of tumor multidrug resistance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310659170.6A CN104689330A (en) | 2013-12-06 | 2013-12-06 | Antitumor drug PEGylation and applications of antitumor drug PEGylation in reversal of tumor multidrug resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104689330A true CN104689330A (en) | 2015-06-10 |
Family
ID=53337145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310659170.6A Pending CN104689330A (en) | 2013-12-06 | 2013-12-06 | Antitumor drug PEGylation and applications of antitumor drug PEGylation in reversal of tumor multidrug resistance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104689330A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106083898A (en) * | 2016-05-31 | 2016-11-09 | 彭咏波 | A kind of tumor-targeting gambogic acid compounds and its production and use |
| WO2017193562A1 (en) * | 2016-05-10 | 2017-11-16 | 浙江海正药业股份有限公司 | Water soluble rapamycin derivative |
| CN108218932A (en) * | 2017-12-27 | 2018-06-29 | 北京大学 | The cancer pre-targeting medicine of agglutinin receptor mediation |
| CN108641075A (en) * | 2018-03-05 | 2018-10-12 | 江苏千之康生物医药科技有限公司 | The double short chain polyalkylene glycol prodrugs and its application of rapamycin and its derivative |
| CN109908365A (en) * | 2019-03-27 | 2019-06-21 | 江苏医药职业学院 | A kind of the phototherapy nanoscale medicine delivery system and preparation method of artitumor multi-medicine-resistant |
| CN110101867A (en) * | 2019-05-16 | 2019-08-09 | 中国医学科学院医药生物技术研究所 | A kind of difunctional antitumor recombinant protein conjugate of PEG modification drunk based on folacin receptor and giant cell |
| CN112707947A (en) * | 2020-12-29 | 2021-04-27 | 湖南华腾制药有限公司 | Adriamycin prodrug, preparation method and application thereof |
| WO2022206796A1 (en) * | 2021-04-02 | 2022-10-06 | 杭州宜生医药科技发展有限公司 | Pegylated rapamycin compound, and preparation method therefor and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101081841A (en) * | 2006-05-29 | 2007-12-05 | 中国科学院上海药物研究所 | Novel 2'-alpha-hydroxyalkyl taxone compound and preparation method thereof |
| CN102631679A (en) * | 2012-03-22 | 2012-08-15 | 天津医科大学 | pH-sensitive pullulan ramification nano-drug carrier, drug-carrying particle and preparation of pH-sensitive pullulan ramification nano-drug carrier and drug-carrying particle |
-
2013
- 2013-12-06 CN CN201310659170.6A patent/CN104689330A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101081841A (en) * | 2006-05-29 | 2007-12-05 | 中国科学院上海药物研究所 | Novel 2'-alpha-hydroxyalkyl taxone compound and preparation method thereof |
| CN102631679A (en) * | 2012-03-22 | 2012-08-15 | 天津医科大学 | pH-sensitive pullulan ramification nano-drug carrier, drug-carrying particle and preparation of pH-sensitive pullulan ramification nano-drug carrier and drug-carrying particle |
Non-Patent Citations (2)
| Title |
|---|
| PENGFEI GOU ET AL.: "《Self-assembling doxorubicin prodrug forming nanoparticles for cancer chemotherapy: synthesis and anticancer study in vitro and in vivo》", 《J. MATER. CHEM. B》 * |
| SREEJA JAYANT ET AL.: "《Targeted Sialic Acid–Doxorubicin Prodrugs for Intracellular Delivery and Cancer Treatment》", 《PHARMACEUTICAL RESEARCH》 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10442835B2 (en) | 2016-05-10 | 2019-10-15 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Water-soluble rapamycin derivatives |
| WO2017193562A1 (en) * | 2016-05-10 | 2017-11-16 | 浙江海正药业股份有限公司 | Water soluble rapamycin derivative |
| CN107949566A (en) * | 2016-05-10 | 2018-04-20 | 浙江海正药业股份有限公司 | Water-soluble rapamycin type derivative |
| CN107949566B (en) * | 2016-05-10 | 2021-09-28 | 浙江海正药业股份有限公司 | Water-soluble rapamycin derivatives |
| CN106083898A (en) * | 2016-05-31 | 2016-11-09 | 彭咏波 | A kind of tumor-targeting gambogic acid compounds and its production and use |
| CN106083898B (en) * | 2016-05-31 | 2019-02-12 | 彭咏波 | A kind of tumor-targeting gambogic acid compounds and its preparation method and application |
| CN108218932A (en) * | 2017-12-27 | 2018-06-29 | 北京大学 | The cancer pre-targeting medicine of agglutinin receptor mediation |
| CN108641075A (en) * | 2018-03-05 | 2018-10-12 | 江苏千之康生物医药科技有限公司 | The double short chain polyalkylene glycol prodrugs and its application of rapamycin and its derivative |
| CN108641075B (en) * | 2018-03-05 | 2019-12-06 | 江苏千之康生物医药科技有限公司 | Rapamycin and double short-chain polyethylene glycol prodrug of rapamycin derivative and application of rapamycin and double short-chain polyethylene glycol prodrug |
| CN109908365A (en) * | 2019-03-27 | 2019-06-21 | 江苏医药职业学院 | A kind of the phototherapy nanoscale medicine delivery system and preparation method of artitumor multi-medicine-resistant |
| CN110101867A (en) * | 2019-05-16 | 2019-08-09 | 中国医学科学院医药生物技术研究所 | A kind of difunctional antitumor recombinant protein conjugate of PEG modification drunk based on folacin receptor and giant cell |
| CN110101867B (en) * | 2019-05-16 | 2022-08-05 | 中国医学科学院医药生物技术研究所 | PEG (polyethylene glycol) modified difunctional anti-tumor recombinant protein conjugate based on folate receptor and macrobiosis |
| CN112707947A (en) * | 2020-12-29 | 2021-04-27 | 湖南华腾制药有限公司 | Adriamycin prodrug, preparation method and application thereof |
| CN112707947B (en) * | 2020-12-29 | 2022-06-17 | 湖南华腾制药有限公司 | Adriamycin prodrug, preparation method and application thereof |
| WO2022206796A1 (en) * | 2021-04-02 | 2022-10-06 | 杭州宜生医药科技发展有限公司 | Pegylated rapamycin compound, and preparation method therefor and use thereof |
| CN115160559A (en) * | 2021-04-02 | 2022-10-11 | 杭州宜生医药科技发展有限公司 | PEG rapamycin compound and preparation method and application thereof |
| CN115160559B (en) * | 2021-04-02 | 2024-02-02 | 杭州宜生医药科技发展有限公司 | PEGylated rapamycin compound and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104689330A (en) | Antitumor drug PEGylation and applications of antitumor drug PEGylation in reversal of tumor multidrug resistance | |
| Liu et al. | Gambogic acid as a candidate for cancer therapy: a review | |
| Ye et al. | A tumor‐specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers | |
| Hatami et al. | Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics | |
| He et al. | Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel | |
| Vergara et al. | Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer | |
| Xie et al. | Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy | |
| Chen et al. | Enhanced antitumor efficacy by methotrexate conjugated Pluronic mixed micelles against KBv multidrug resistant cancer | |
| CN104177624B (en) | Dual Sensitive amphipathic three block copolymer containing disulfide bond and acylhydrazone key and preparation method and application | |
| Shen et al. | HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment | |
| Xia et al. | Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy | |
| Hong et al. | A novel folic acid receptor-targeted drug delivery system based on curcumin-loaded β-cyclodextrin nanoparticles for cancer treatment | |
| Zhou et al. | Polymeric micelles loading with ursolic acid enhancing anti-tumor effect on hepatocellular carcinoma | |
| Zhou et al. | A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity | |
| Wen et al. | A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer | |
| Ni et al. | Lymph cancer chemotherapy: Delivery of doxorubicin–gemcitabine prodrug and vincristine by nanostructured lipid carriers | |
| CN104523723A (en) | Mitochondria-targeting micelle drug delivery system capable of reversing drug resistance of tumor | |
| CN104530256A (en) | Hyaluronic acid-vitamin E succinate polymer as well as preparation and application thereof | |
| Shi et al. | Active-targeting docetaxel-loaded mixed micelles for enhancing antitumor efficacy | |
| Tang et al. | Therapeutic effect of sorafenib-loaded TPGS-b-PCL nanoparticles on liver cancer | |
| Liang et al. | In vivo pharmacokinetics, biodistribution and antitumor effect of paclitaxel-loaded micelles based on α-tocopherol succinate-modified chitosan | |
| Wang et al. | Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo | |
| Shen et al. | Co-delivery anticancer drug nanoparticles for synergistic therapy against lung cancer cells | |
| Moghaddam et al. | Fabrication of carboxymethyl chitosan nanoparticles to deliver paclitaxel for melanoma treatment | |
| Liu et al. | Platinated graphene oxide: A nanoplatform for efficient gene-chemo combination cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150610 |